clinical trial glp 1 Another milestone in the evolution of GLP-1-based diabetes therapies GLP-1 Drug Pipeline 2026 |

Currently, only two GLP-1s are approved by the FDA to treat obesity: Wegovy and Saxenda (liraglutide)

The studys results will complement existing clinical outcomes data from related trials and contribute to a better understanding of semaglutides potential cardiovascular benefits

GLP-1 households decreased food spending by -1.6% in the first nine months of the year versus year-agothree times faster than non-GLP-1 households (-0.5%)

Importantly, the combination of FGF21 and LepAB further improved liver function by reducing lipid droplet accumulation and liver fibrosis (Fig

However, semaglutide is also used in other medications, such as Wegovy, which contains a higher dose and is approved specifically for weight loss